Welcome to our dedicated page for Ethos Technologies news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Ethos Technologies stock.
Ethos Technologies Inc. reports developments tied to its digital life insurance platform, which connects consumers, independent agents and insurance carriers through online underwriting and policy issuance tools. The company distributes life insurance products in direct-to-consumer and third-party channels and earns carrier commissions and administrator-service revenue from activated policies.
Recurring updates include quarterly results, direct and third-party channel revenue, policy activation trends, and technology integrations that expand digital purchasing. Company announcements also cover carrier collaborations and product additions, including whole life, final expense, and indexed universal life offerings delivered through Ethos' platform.
aTyr Pharma, Inc. (Nasdaq: LIFE) has signed a contract with Lonza for the production of ATYR2810, a monoclonal antibody targeting Neuropilin-2 (NRP2), which is in preclinical development for cancer. This partnership will utilize Lonza’s Ibex® Design to manufacture cGMP material for ATYR2810, supporting both drug substance and product for toxicological studies and early clinical development. The agreement underlines aTyr's focus on advancing ATYR2810 for aggressive tumors linked to NRP2, aiming for eventual clinical trials.
aTyr Pharma announces promising findings for ATYR2810, a monoclonal antibody targeting Neuropilin-2, at the 2021 AACR Annual Meeting. The preclinical studies showed that ATYR2810 significantly inhibited tumor growth in non-small cell lung cancer models when used alone and enhanced the effects of chemotherapy in triple-negative breast cancer models. The research, conducted in collaboration with UMass Medical School, suggests that ATYR2810 may overcome tumor resistance and provide a new therapeutic avenue for treating aggressive cancers. The company aims to advance ATYR2810 to clinical trials.
aTyr Pharma (Nasdaq: LIFE) appointed Andrea Wilson as a patient advisor, focusing on strategies for the clinical program of ATYR1923 in pulmonary sarcoidosis. Ms. Wilson, a sarcoidosis patient and the co-founder of the Foundation for Sarcoidosis Research, aims to leverage her advocacy experience to support patient strategies. ATYR1923 is currently in a Phase 1b/2a trial, targeting inflammatory lung diseases, particularly pulmonary sarcoidosis, affecting approximately 150,000 to 200,000 Americans.
aTyr Pharma has completed enrollment for its clinical trial of ATYR1923 in patients with pulmonary sarcoidosis, with data expected in Q3 2021. Positive results from a Phase 2 trial in COVID-19 patients demonstrated a favorable safety profile and potential efficacy. The company reported revenues of $10.5 million in 2020, largely due to the Kyorin Agreement. As of year-end 2020, aTyr had $31.7 million in cash. The company anticipates increased R&D expenses in 2021 to further develop ATYR1923 and ATYR2810.
aTyr Pharma (Nasdaq: LIFE) announced that it will release its fourth-quarter and full-year 2020 financial results on March 23, 2021, after market close. The management will hold a conference call and webcast at 5:00 PM EDT / 2:00 PM PDT to discuss these results and provide a corporate update. The company focuses on developing innovative medicines using novel biological pathways, particularly through its clinical-stage candidate ATYR1923, aimed at treating inflammatory lung diseases.
aTyr Pharma announced positive results from the Phase 2 trial of ATYR1923 in hospitalized COVID-19 patients, showing a reduction in inflammatory cytokines, including IL-6 and IFNγ. The trial involved 32 patients who demonstrated improved recovery times, with a median of 5.5 days under treatment compared to 6 days for the placebo. The results support ATYR1923’s potential in inflammatory lung diseases, specifically sarcoidosis. These findings, while not statistically powered, indicate the drug's activity and an added anti-inflammatory benefit. Further studies are anticipated to confirm efficacy.
aTyr Pharma (Nasdaq: LIFE) has announced two upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 10-15 and May 17-21. The first poster will focus on the efficacy of the NRP2 targeting antibody ATYR2810 against non-small cell lung cancer, while the second will discuss the impact of a domain-specific antibody on aggressive breast cancer treatment. Both studies highlight the potential of NRP2 as a therapeutic target in oncology, emphasizing aTyr's commitment to innovative cancer therapies.
aTyr Pharma has appointed Judith Varner, Ph.D., as a scientific advisor, focusing on Neuropilin-2 (NRP2) and its potential in cancer therapies. Dr. Varner's expertise will support aTyr's NRP2 antibody program, including ATYR2810. Recent research highlights NRP2's role in tumor progression, emphasizing its therapeutic promise. aTyr aims to advance its understanding of NRP2's signaling pathways for innovative cancer treatments, positioning itself as a leader in anti-cancer therapeutics.
aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company, announced participation in four virtual investor conferences in March 2021. Dr. Sanjay S. Shukla, President and CEO, will deliver a corporate overview and engage in a panel discussion on immuno-oncology at the ROTH Conference. Key events include the H.C. Wainwright Global Life Sciences Conference (March 9-10), the ROTH Conference (March 15-17), the Oppenheimer Healthcare Conference (March 17), and the Maxim Group Conference (March 17-18). Presentations will be available for registered attendees and a replay will be accessible on the company's website.
aTyr Pharma, Inc. (Nasdaq: LIFE) has announced the initiation of two new discovery programs from its tRNA synthetase platform, focusing on Alanyl-tRNA Synthetase (AARS) and Aspartyl-tRNA Synthetase (DARS) fragments in immunology, fibrosis, and cancer. This effort aims to explore how these fragments affect natural killer (NK) cell biology, potentially leading to innovative therapies. The announcement follows a successful poster presentation at the SLAS 2021 conference, showcasing the interaction of these fragments with immune cells. aTyr’s current pipeline includes ATYR1923, targeting the Neuropilin-2 receptor.